Lucifer James
The pharmaceutical industry is undergoing a seismic transformation. Driven by artificial intelligence (AI), digital therapeutics, and evolving regulatory frameworks, drug licensing is no longer confined to traditional pathways. These innovations promise faster approvals, personalized treatments, and broader access—but they also raise new challenges around safety, ethics, and compliance. As we look ahead, the future of drug licensing will be defined by how effectively stakeholders adapt to these emerging trends.
